
Eli Lilly’s tirzepatide – presumably the biggest competition for Novo Nordisk’s new generation of diabetes drugs – is not more effective than other type 2 diabetes treatments on the market.
This was the conclusion reached by experts from the Institute for Clinical and Economic Review (ICER), an independent US-based research institute that evaluates the efficacy of new drugs.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app